keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal Serogroup B Vaccine

keyword
https://www.readbyqxmd.com/read/28441109/meningococcal-serogroup-b-vaccine-knowledge-and-acceptability-among-parents-in-italy
#1
Teresa Morrone, Francesco Napolitano, Luciana Albano, Gabriella Di Giuseppe
This study aimed to evaluate the knowledge and attitudes about Meningococcal meningitis B and the relative vaccine for children among a sample of parents in Italy. A cross-sectional investigation was conducted from October to December 2015 among a sample of 910 parents in the geographic area of Naples and Salerno (Italy). In total, 543 of 910 parents returned a completed questionnaire for a response rate of 59.7%. Almost all parents had heard about meningitis (95.8%), 79.8% of these knew the mode of transmission (through respiratory droplets) and 62...
April 25, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28433330/bivalent-rlp2086-trumenba%C3%A2-development-of-a-well-characterized-vaccine-through-commercialization
#2
Khurram Sunasara, John Cundy, Sriram Srinivasan, Brad Evans, Weiqiang Sun, Scott Cook, Eric Bortell, John Farley, Daniel Griffin, Michele Bailey Piatchek, Katherine Arch-Douglas
The phrase "Process is the Product" is often applied to biologics, including multicomponent vaccines composed of complex components that evade complete characterization. Vaccine production processes must be defined and locked early in the development cycle to ensure consistent quality of the vaccine throughout scale-up, clinical studies, and commercialization. This approach of front-loading the development work helped facilitate the accelerated approval of the Biologic License Application for the well-characterized vaccine bivalent rLP2086 (Trumenba®, Pfizer Inc) in 2014 under Breakthrough Therapy Designation...
April 19, 2017: Vaccine
https://www.readbyqxmd.com/read/28418307/serogroup-b-meningococcal-disease-vaccine-recommendations-at-a-university-new-jersey-usa-2016
#3
Heidi M Soeters, Jill Dinitz-Sklar, Prathit A Kulkarni, Jessica R MacNeil, Lucy A McNamara, Elizabeth Zaremski, How-Yi Chang, Eduardo Lujan, Dan Granoff, Melodee Lasky, Barbara Montana
In response to a university-based serogroup B meningococcal disease outbreak, the serogroup B meningococcal vaccine Trumenba was recommended for students, a rare instance in which a specific vaccine brand was recommended. This outbreak highlights the challenges of using molecular and immunologic data to inform real-time response.
May 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28375029/emerging-experience-with-meningococcal-serogroup-b-protein-vaccines
#4
REVIEW
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli
The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials...
May 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28368526/licensed-meningococcal-serogroup-b-vaccine-induced-immunity-against-invasive-disease-does-not-reflect-protection-against-nasal-colonization-in-a-humanized-mouse-model
#5
Carolyn M Buckwalter, Elissa G Currie, Raymond S W Tsang, Scott D Gray-Owen
Background: The 4CMenB vaccine is an outer membrane vesicle and recombinant protein-based vaccine recently licensed to protect against serogroup B meningococcal disease. It remains unknown whether this vaccine will prevent carriage or transmission, key aspects in long-term vaccine success and disease eradication. Methods: Employing a 'humanized' transgenic mouse model of nasal colonization, a systematic approach was taken to estimate the potential for carriage prevention against antigenically-diverse Neisseria meningitidis strains, and to compare this protection to an invasive meningococcal disease challenge model...
March 27, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28366725/meningococcal-serogroup-b-strain-coverage-of-the-multicomponent-4cmenb-vaccine-with-corresponding-regional-distribution-and-clinical-characteristics-in-england-wales-and-northern-ireland-2007-08-and-2014-15-a-qualitative-and-quantitative-assessment
#6
Sydel R Parikh, Lynne Newbold, Stephanie Slater, Maria Stella, Monica Moschioni, Jay Lucidarme, Rosita De Paola, Maria Giuliani, Laura Serino, Stephen J Gray, Stephen A Clark, Jamie Findlow, Mariagrazia Pizza, Mary E Ramsay, Shamez N Ladhani, Ray Borrow
BACKGROUND: The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningococcal Antigen Typing System (MATS) was used to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 in England and Wales (MATS coverage). We aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15, before 4CMenB introduction; compare strain coverage between 2007-08 and 2014-15; and investigate associations between MATS coverage, age, region, and disease outcomes...
March 30, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28356256/recent-progress-in-the-prevention-of-serogroup-b-meningococcal-disease
#7
Ian M Feavers, Martin C J Maiden
The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of four decades vaccine development has focused on sub-capsular, protein antigens, first with outer membrane vesicle (OMV) vaccines against epidemic outbreaks, and more recently on new multicomponent vaccines designed to offer better cross-protection against the antigenically diverse strains responsible for endemic disease. Because of the low incidence of meningococcal disease, the protective efficacy of these vaccines has not been determined in clinical studies and their licensure has been based on serological data; however, the serological assays used to predict protective coverage have limitations...
March 29, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28351732/prevalence-of-factor-h-binding-protein-sub-variants-among-neisseria-meningitidis-in-china
#8
Fenglin Shi, Aiyu Zhang, Bingqing Zhu, Yuan Gao, Li Xu, Yixing Li, Zundong Yin, Junhong Li, Na Xie, Zhujun Shao
OBJECTIVE: To study the prevalence of the fHbp genes in Neisseria meningitidis (N. meningitidis) isolates for further evaluation and development of serogroup B meningococcal vaccines in China. METHODS: A panel of 1012 N. meningitidis strains was selected from the national culture collection from 1956 to 2016, according to the years of isolation, locations, and strain sources. These were tested by FHbp variant typing. Multi-locus sequence typing (MLST) was performed on 822 of these samples, including 242 strains from clinical strains and 580 carrier-derived strains...
March 25, 2017: Vaccine
https://www.readbyqxmd.com/read/28347501/knowledge-attitudes-beliefs-and-behaviors-of-university-students-faculty-and-staff-during-a-meningococcal-serogroup-b-outbreak-vaccination-program
#9
D M MacDougall, J M Langley, L Li, L Ye, D MacKinnon-Cameron, K A Top, S A McNeil, B A Halperin, A Swain, J A Bettinger, E Dubé, G De Serres, S A Halperin
OBJECTIVES: During an outbreak of invasive meningococcal B disease on a university campus, we explored the knowledge, attitudes, beliefs, and behaviors of members of the university community in relation to the disease, the vaccine, and the vaccination program. DESIGN: All students, faculty and staff were invited by email to participate in a 71-item online survey, which was administered after completion of the mass clinics for the first and second doses of a meningococcal B vaccination program...
March 24, 2017: Vaccine
https://www.readbyqxmd.com/read/28344804/multicomponent-meningococcal-b-vaccination-4cmenb-of-adolescents-and-college-students-in-the-united-states
#10
REVIEW
Angelika Banzhoff
Meningococcal disease is rare, easily misdiagnosed, and potentially deadly. Diagnosis in the early stages is difficult and the disease often progresses extremely rapidly. In North America, the incidence of invasive meningococcal disease (IMD) is highest in infants and young children, with a secondary peak in adolescents, a population predominantly responsible for the carriage of disease. Neisseria meningitidis serogroup B (MenB) accounts for a large proportion of meningococcal disease in North America, with documented outbreaks in three universities in the United States (US) during 2008-2013...
February 2017: Therapeutic Advances in Vaccines
https://www.readbyqxmd.com/read/28343777/neisseria-meningitidis-nasopharyngeal-carriage-during-the-hajj-a-cohort-study-evaluating-the-need-for-ciprofloxacin-prophylaxis
#11
Ziad A Memish, Jaffar A Al-Tawfiq, Malak Almasri, Esam I Azhar, Muhammad Yasir, Muneera S Al-Saeed, Huda Ben Helaby, Ray Borrow, Abdulhafeez Turkistani, Abdallah Assiri
BACKGROUND: The annual Muslim pilgrimage has the potential of increase risk for acquisition of Neisseria meningitidis. Here, we evaluate the Hajj impact on the prevalence of N. meningitidis carriage in a paired and non-paired cohort of pilgrims. Secondary objectives were to calculate the compliance with recommended vaccination. METHODS: This is a prospective paired (arriving and departing), non-paired arriving and non-paired departing cohort study with the collection of nasopharyngeal samples at the start and the end of the Hajj...
March 23, 2017: Vaccine
https://www.readbyqxmd.com/read/28334397/does-post-implementation-vaccine-effectiveness-data-support-pre-implementation-predictions-of-4cmenb-utility
#12
Jamie Findlow, Ray Borrow
Meningococcal serogroup B vaccines have been licensed on the basis of safety and immunogenicity data without efficacy studies. Establishing the breadth of coverage of these new vaccines has proved difficult and relied on correlates of protection such as serum bactericidal antibody and a novel assays such as the meningococcal antigen typing system. The demonstration of the effectiveness of 4CMenB in a reduced infant dose schedule together with detailed phenotypic and genotypic information gained from isolates and sera from cases of invasive MenB disease in vaccine eligible infants will enable a re-evaluation of our knowledge of correlates of protection...
March 1, 2017: Pathogens and Disease
https://www.readbyqxmd.com/read/28318767/immunogenicity-and-safety-of-concomitant-administration-of-meningococcal-serogroup-b-4cmenb-and-serogroup-c-menc-crm-vaccines-in-infants-a-phase-3b-randomized-controlled-trial
#13
Marco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, Edson Duarte Moreira, Eduardo Jorge da Fonseca Lima, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: After implementation of routine infant MenC vaccination, MenB remains a serious cause of meningococcal disease, yet to be targeted by vaccination programs in several countries. This study (NCT01339923) investigated the immunogenicity and safety of MenC CRM-conjugated vaccine (MenC-CRM) concomitantly administered with MenB vaccine (4CMenB). METHODS: Infants (N=251) were randomised 1:1 to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM alone (Group 2) at 3 and 5months (M3, M5) and a booster at 12months of age (M12), and pneumococcal vaccine at M3, M5, M7, M12...
March 15, 2017: Vaccine
https://www.readbyqxmd.com/read/28314560/the-epidemiology-of-invasive-meningococcal-disease-in-eu-eea-countries-2004-2014
#14
Robert Whittaker, Joana Gomes Dias, Miriam Ramliden, Csaba Ködmön, Assimoula Economopoulou, Netta Beer, Lucia Pastore Celentano
BACKGROUND: Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia although infection by some serogroups may be prevented through vaccination. We aimed to describe the epidemiology of IMD in EU/EEA countries during 2004-2014 to monitor serogroup- and age-specific trends, and compare country trends by the period of meningococcal C conjugate (MCC) vaccine introduction. METHODS: We analysed IMD surveillance data by age, gender, serogroup, country and outcome...
March 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28277801/the-immunogenicity-and-safety-of-a-hib-menac-vaccine-a-non-inferiority-randomized-observer-blind-trial-in-infants-aged-3-5-months
#15
RANDOMIZED CONTROLLED TRIAL
Yu-Xiao Wang, Hong Tao, Jian-Li Hu, Jing-Xin Li, Wei-Ming Dai, Jin-Fang Sun, Pei Liu, Jie Tang, Wen-Yu Liu, Feng-Cai Zhu
BACKGROUND: The objective of this study was to evaluate the immunogenicity and safety of the novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup A and C-tetanus toxoid conjugate vaccine (Hib-MenAC). METHODS: We conducted a non-inferiority, randomized, observer-blind, positive control clinical trial in 900 healthy infants aged between 3-5 months in Funing County, Jiangsu Province, China. Participants were randomly allocated, in a ratio of 2:1 (block = 6), to receive experimental combined Hib-MenAC vaccines co-administrated with placebo or the co-administration of licensed Hib vaccine and MenAC vaccine, according to a three-dose immunization schedule...
May 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28253232/erratum-vol-66-no-5
#16
(no author information available yet)
In the report "Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017," on page 138, the fifth bullet point under the heading "Meningococcal vaccination" should have read "Young adults aged 16 through 23 years (preferred age range is 16 through 18 years) who are healthy and not at increased risk for serogroup B meningococcal disease may receive either a 2-dose series of MenB-4C at least 1 month apart or a 2-dose series of MenB-FHbp at 0 and 6 months for short-term protection against most strains of serogroup B meningococcal disease...
March 3, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28196734/bactericidal-activity-of-sera-from-adolescents-vaccinated-with-bivalent-rlp2086-against-meningococcal-serogroup-b-outbreak-strains-from-france
#17
Muhamed-Kheir Taha, Julio Cesar Hawkins, Paul Liberator, Ala-Eddine Deghmane, Lubomira Andrew, Li Hao, Thomas R Jones, Lisa K McNeil, Robert E O'Neill, John L Perez, Kathrin U Jansen, Annaliesa S Anderson
OBJECTIVES: Bivalent rLP2086 (Trumenba®; MenB-FHbp), composed of two factor H binding proteins (FHbps), is a vaccine approved in the United States for prevention of Neisseria meningitidis serogroup B (MnB) invasive meningococcal disease (IMD). Bactericidal activity of sera from subjects vaccinated with bivalent rLP2086 was assessed against MnB isolates from recent disease outbreaks in France. METHODS: MnB isolates from IMD cases were characterized by whole genome sequencing and FHbp expression was assessed using a flow cytometry-based assay...
February 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28192234/meningococcal-carriage-in-dutch-adolescents-and-young-adults-a-cross-sectional-and-longitudinal-cohort-study
#18
Mariëtte B van Ravenhorst, Merijn W Bijlsma, Marlies A van Houten, Veerle M D Struben, Annaliesa S Anderson, Joseph Eiden, Hao Li, Kathrin U Jansen, Hal Jones, Nicholas Kitchin, Louise Pedneault, Elisabeth A M Sanders, Arie van der Ende
OBJECTIVES: Current information on rates and dynamics of meningococcal carriage is essential for public health policy. This study aimed to determine meningococcal carriage prevalence, its risk factors and duration in the Netherlands, where meningococcal C vaccine coverage is >90%. Several methods to identify serogroups of meningococcal carriage isolates among adolescent and young adults were compared. METHODS: Oropharyngeal swabs from 1715 subjects 13-23 years of age were collected in 2013-2014; 300 were prospectively followed over 8 months...
February 10, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28167517/the-need-to-optimize-adolescent-immunization
#19
Henry H Bernstein, Joseph A Bocchini
The adolescent period heralds the pediatric patient's transition into adulthood. It is a time of dynamic development during which effective preventive care measures can promote safe behaviors and the development of lifelong health habits. One of the foundations of preventive adolescent health care is timely vaccination, and every visit can be viewed as an opportunity to update and complete an adolescent's immunizations.In the past decade, the adolescent immunization schedule has expanded to include 2 doses of quadrivalent meningococcal conjugate vaccine, 1 dose of tetanus, diphtheria, acellular pertussis, absorbed vaccine, 2 or 3 doses of human papillomavirus vaccine, depending on the child's age, and an annual influenza vaccine...
March 2017: Pediatrics
https://www.readbyqxmd.com/read/28158417/meningococcal-carriage-evaluation-in-response-to-a-serogroup-b-meningococcal-disease-outbreak-and-mass-vaccination-campaign-at-a-college-rhode-island-2015-2016
#20
Heidi M Soeters, Melissa Whaley, Nicole Alexander-Scott, Koren V Kanadanian, Jessica R MacNeil, Stacey W Martin, Lucy A McNamara, Kenneth Sicard, Cynthia Vanner, Jeni Vuong, Xin Wang, Utpala Bandy, Manisha Patel
Background.: Serogroup B meningococcal disease caused 7 US university outbreaks during 2013-2016. Neisseria meningitidis can be transmitted via asymptomatic nasopharyngeal carriage. MenB-FHbp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a college outbreak. We investigated MenB-FHbp impact on meningococcal carriage. Methods.: Four cross-sectional surveys were conducted in conjunction with MenB-FHbp vaccination campaigns...
April 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
49014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"